Other Medicinal Products for Human Use
Medicines for which the Paul-Ehrlich-Institut is responsible, but which are not assigned to a particular group of medicines.
Name
|
Marketing Authorisation Holder
|
Kind of Vaccine
|
License Number
|
License Date
|
Further Information
|
Uro-Vaxom
|
Immuntherapeutikum bei rezidivierenden Harnwegsinfektionen
|
A.C.A Müller ADAG Pharma AG
|
weitere |
PEI.H.11915.01.1 |
11.02.2019 |
PharmNet.Bund
|
Uro-Vaxom, 6 mg Hartkapseln
|
E. coli-Fraktionen
Immuntherapeutikum bei rezidivierenden Harnwegsinfektionen
|
Orifarm GmbH
|
weitere |
PEI.H.12062.01.1 |
16.07.2021 |
|
Uro-Vaxom, 6mg, Hartkapseln
|
Immuntherapeutikum bei rezidivierenden Harnwegsinfektionen
|
Abacus Medicine A/S
, DK
|
weitere |
PEI.H.11979.01.1 |
21.09.2021 |
|
BCG Apogepha 100 mg
|
L03AX03 Immunstimulans
Therapie des oberflächlichen Harnblasentumors
|
APOGEPHA Arzneimittel GmbH
|
weitere |
PEI.H.12057.01.1 |
01.08.2022 |
|
BCGepha 100 mg
|
Immunstimmulanzien
|
APOGEPHA Arzneimittel GmbH
|
weitere |
PEI.H.12169.01.1 |
22.05.2023 |
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 519 in BAnz AT 26.07.2024 B6.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.